ATE228006T1 - Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren - Google Patents

Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren

Info

Publication number: ATE228006T1
Authority: AT; Austria
Prior art keywords: vip; mammals; endotoxic shock; medication; create
Prior art date: 1998-04-17

Application number

AT99913324T

Other languages

English (en)

Inventor

Gomariz Rosa Perez

Martinez Javier Leceta

Mora Mario Delgado

Mora Carmen Martinez

Original Assignee

Univ Madrid Complutense

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-17

Filing date

1999-04-16

Publication date

2002-12-15

1999-04-16 Application filed by Univ Madrid Complutense filed Critical Univ Madrid Complutense

2002-12-15 Application granted granted Critical

2002-12-15 Publication of ATE228006T1 publication Critical patent/ATE228006T1/de

Links

206010014824 Endotoxic shock Diseases 0.000 title abstract 2
241000124008 Mammalia Species 0.000 title abstract 2
206010040070 Septic Shock Diseases 0.000 title abstract 2
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
102000055135 Vasoactive Intestinal Peptide Human genes 0.000 abstract 2
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 abstract 2
VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 abstract 2
239000012190 activator Substances 0.000 abstract 1
108060000200 adenylate cyclase Proteins 0.000 abstract 1
102000030621 adenylate cyclase Human genes 0.000 abstract 1
230000017074 necrotic cell death Effects 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
230000001173 tumoral effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Manufacture Of Tobacco Products (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Silicates, Zeolites, And Molecular Sieves (AREA)

AT99913324T 1998-04-17 1999-04-16 Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren ATE228006T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ES009800814A ES2138561B1 (es)	1998-04-17	1998-04-17	Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos.
PCT/ES1999/000101 WO1999053944A1 (es)	1998-04-17	1999-04-16	Metodo para el tratamiento del 'shock' endotoxico en mamiferos

Publications (1)

Publication Number	Publication Date
ATE228006T1 true ATE228006T1 (de)	2002-12-15

Family

ID=8303495

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99913324T ATE228006T1 (de)	1998-04-17	1999-04-16	Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren

Country Status (10)

Country	Link
US (1)	US6429188B1 (de)
EP (1)	EP1002542B1 (de)
JP (1)	JP2002507224A (de)
AT (1)	ATE228006T1 (de)
AU (1)	AU3148699A (de)
CA (1)	CA2294980A1 (de)
DE (1)	DE69904010T2 (de)
ES (1)	ES2138561B1 (de)
PT (1)	PT1002542E (de)
WO (1)	WO1999053944A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60002143T2 (de) *	1999-06-04	2004-03-18	Universidad Complutense De Madrid	Behandlung autoimmunerkrankungen in säugern
WO2003096024A1 (en) *	2002-05-08	2003-11-20	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 2 (vpac2)
US7547450B2 (en) *	2002-10-24	2009-06-16	Nestec Ltd.	Senior feline food
AU2003284678B2 (en) *	2003-02-24	2006-02-23	Morinaga Milk Industry Co., Ltd.	Interleukin 6 production inhibitor
US8841255B2 (en)	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
CN101384272B (zh)	2005-12-20	2013-05-01	杜克大学	用于递送具有增强的药理性质的活性剂的方法和组合物
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
US8178495B2 (en)	2008-06-27	2012-05-15	Duke University	Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
PL3311828T3 (pl) *	2009-08-14	2021-11-22	Phasebio Pharmaceuticals, Inc.	Zmodyfikowane wazoaktywne peptydy jelitowe
CA2873553C (en)	2011-06-06	2020-01-28	Phasebio Pharmaceuticals, Inc.	Use of modified vasoactive intestinal peptides in the treatment of hypertension
CA2947982C (en)	2014-05-08	2022-11-29	Phasebio Pharmaceuticals, Inc.	Methods and compositions for treating cystic fibrosis
CA2976038A1 (en)	2015-02-09	2016-08-18	Phasebio Pharmaceuticals, Inc.	Methods and compositions for treating muscle disease and disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6429221B1 (en) *	1994-12-30	2002-08-06	Celgene Corporation	Substituted imides

1998
- 1998-04-17 ES ES009800814A patent/ES2138561B1/es not_active Expired - Fee Related
1999
- 1999-04-16 CA CA002294980A patent/CA2294980A1/en not_active Abandoned
- 1999-04-16 AT AT99913324T patent/ATE228006T1/de not_active IP Right Cessation
- 1999-04-16 JP JP55251999A patent/JP2002507224A/ja not_active Ceased
- 1999-04-16 US US09/446,352 patent/US6429188B1/en not_active Expired - Fee Related
- 1999-04-16 AU AU31486/99A patent/AU3148699A/en not_active Abandoned
- 1999-04-16 PT PT99913324T patent/PT1002542E/pt unknown
- 1999-04-16 EP EP99913324A patent/EP1002542B1/de not_active Expired - Lifetime
- 1999-04-16 WO PCT/ES1999/000101 patent/WO1999053944A1/es not_active Ceased
- 1999-04-16 DE DE69904010T patent/DE69904010T2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2138561A1 (es)	2000-01-01
PT1002542E (pt)	2003-04-30
CA2294980A1 (en)	1999-10-28
EP1002542A1 (de)	2000-05-24
JP2002507224A (ja)	2002-03-05
ES2138561B1 (es)	2000-07-01
WO1999053944A1 (es)	1999-10-28
DE69904010T2 (de)	2003-08-21
DE69904010D1 (de)	2003-01-02
AU3148699A (en)	1999-11-08
US6429188B1 (en)	2002-08-06
EP1002542B1 (de)	2002-11-20

Similar Documents

Publication	Publication Date	Title
ATE233558T1 (de)	2003-03-15	Verwendung von strontiumsälze zur behandlung von arthrose
DE69616376D1 (de)	2001-11-29	Verwendung von Tiagabin zur Behandlung von Schlafstörungen
ATE228006T1 (de)	2002-12-15	Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren
DE3779149D1 (de)	1992-06-25	Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
ATE281840T1 (de)	2004-11-15	Behandlung von diarrhoe
DE69634900D1 (de)	2005-08-04	Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ATE225176T1 (de)	2002-10-15	Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE342278T1 (de)	2006-11-15	Verfahren zur behandlung von diabetes mittels kgf
ATE110958T1 (de)	1994-09-15	Verwendung von sertralin zur behandlung verfrühter ejakulation.
ATE258796T1 (de)	2004-02-15	Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE253061T1 (de)	2003-11-15	Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
DE59202663D1 (de)	1995-08-03	Verwendung eines UV-Strahlers zur Behandlung von Oberflächen.
ATE289816T1 (de)	2005-03-15	Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE106736T1 (de)	1994-06-15	Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
ATE126056T1 (de)	1995-08-15	Mittel zur behandlung von seniler demenz, gedächtnisstörungen und ähnlichen zuständen.
DE59902666D1 (de)	2002-10-17	Edelfosin zur behandlung von hirntumoren
ATE217191T1 (de)	2002-05-15	Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE222491T1 (de)	2002-09-15	Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
ATE212845T1 (de)	2002-02-15	Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
ATE291918T1 (de)	2005-04-15	Kombinationstherapie zur behandlung von tumoren
ATE187648T1 (de)	2000-01-15	Zusammensetzungen enthaltend lipoprotein- associated-coagulation-inhibitor (laci) zur herstellung eines medikaments zur behandlung von akuten oder chronischen enzündungen
ATE69163T1 (de)	1991-11-15	Verwendung von oligopeptiden zur behandlung von cerebralen stoerungen.
EP1056458A4 (de)	2001-06-20	Methoden zur behandlung von schmerzen, einscliesslich chronischen und frauenspezifischen schmerzen
ATE251462T1 (de)	2003-10-15	Verfahren zur behandlung von narbengewebe
ATE234613T1 (de)	2003-04-15	Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen

Legal Events

Date

Code

Title

Description

2003-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1002542

Country of ref document: EP

2008-01-15

REN

Ceased due to non-payment of the annual fee